A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal cancer is showing promising results, according to a recently published study.

Researchers from the University of California said patients "developed strong immune responses" to the new vaccine and "remained disease-free."

Phase 1 trial

Dig deeper:

The vaccine, called ELI-002 2P, showed evidence of triggering a powerful and lasting immune response.

It may also help prevent or delay cancer regrowth in high-risk patients with tumors that are driven by KRAS mutations, according to a UCLA Health news release.

The study, published in Nature Medicine on August 11, found that 21 of the 25 participants had an immune response to the KRAS mutations.

The patients gene

See Full Page